___

• 1. Aggarwal EH, Jain D, Jain P, Kaverappa V, Kumar A, Yadav S. Tuberous sclerosis - A case report and review of literature. Cumhuriyet Med J 2012; 34: 79-85.
• 2. Yates JR, Maclean C, Higgins JN, Humphrey A, le Maréchal K, Clifford M, Carcani-Rathwell I, Sampson JR, Bolton PF; Tuberous Sclerosis 2000 Study Group. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child 2011; 96: 1020-5.
• 3. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011; 4: 476-95.
• 4. Davies DM. Tuberous sclerosis: from gene to targeted therapy. Clinical Medicine 2012; 12: s7-s10.
• 5. Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 2012; 46: 267-75.
• 6. Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 2012; 53: 1119-30.
• 7. Russo E, Citraro R, Donato G, Camastra C, Iuliano R, Cuzzocrea S, Constanti A, De Sarro G. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2012.
• 8. Jentarra GM, Rice SG, Olfers S, Saffen D, Narayanan V. Evidence for population variation in TSC1 and TSC2 gene expression. BMC Med Genet 2011; 12: 29.